1. Home
  2. GANX vs NTZ Comparison

GANX vs NTZ Comparison

Compare GANX & NTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • NTZ
  • Stock Information
  • Founded
  • GANX 2017
  • NTZ 1959
  • Country
  • GANX United States
  • NTZ Italy
  • Employees
  • GANX N/A
  • NTZ N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • NTZ Home Furnishings
  • Sector
  • GANX Health Care
  • NTZ Consumer Discretionary
  • Exchange
  • GANX Nasdaq
  • NTZ Nasdaq
  • Market Cap
  • GANX 51.8M
  • NTZ 41.6M
  • IPO Year
  • GANX 2021
  • NTZ 1993
  • Fundamental
  • Price
  • GANX $1.44
  • NTZ $2.62
  • Analyst Decision
  • GANX Strong Buy
  • NTZ
  • Analyst Count
  • GANX 5
  • NTZ 0
  • Target Price
  • GANX $8.20
  • NTZ N/A
  • AVG Volume (30 Days)
  • GANX 275.2K
  • NTZ 22.4K
  • Earning Date
  • GANX 08-11-2025
  • NTZ 07-02-2025
  • Dividend Yield
  • GANX N/A
  • NTZ N/A
  • EPS Growth
  • GANX N/A
  • NTZ N/A
  • EPS
  • GANX N/A
  • NTZ N/A
  • Revenue
  • GANX N/A
  • NTZ $337,653,480.00
  • Revenue This Year
  • GANX N/A
  • NTZ N/A
  • Revenue Next Year
  • GANX N/A
  • NTZ N/A
  • P/E Ratio
  • GANX N/A
  • NTZ N/A
  • Revenue Growth
  • GANX N/A
  • NTZ N/A
  • 52 Week Low
  • GANX $0.89
  • NTZ $2.15
  • 52 Week High
  • GANX $3.19
  • NTZ $6.27
  • Technical
  • Relative Strength Index (RSI)
  • GANX 34.87
  • NTZ 30.71
  • Support Level
  • GANX $1.55
  • NTZ $2.55
  • Resistance Level
  • GANX $1.72
  • NTZ $2.83
  • Average True Range (ATR)
  • GANX 0.12
  • NTZ 0.19
  • MACD
  • GANX -0.02
  • NTZ 0.01
  • Stochastic Oscillator
  • GANX 6.12
  • NTZ 55.29

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About NTZ Natuzzi S.p.A.

Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.

Share on Social Networks: